HillSignal

TICKER INTELLIGENCE

MetLife, Inc. ($MET)

$100.76▲ 0.6% (7d)

NYSE/NASDAQ: MET

Washington Intelligence

7

Active Bills

0

Gov't Contracts

50

Congressional Trades

$MET is a publicly traded company in the Finance sector. This company operates across Finance and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 7 active Congressional signals mentioning $MET, including 7 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.

Congressional Trades in $MET

50 filings
Alan Armstrong
BUY $1,001 - $15,000 — MetLife, Inc. Common Stock
2026-07-21
Rohit Khanna
BUY $1,001 - $15,000 — Metlife Inc
2026-07-06
Rohit KhannaD-CA
BUY $1,001 - $15,000 — METLIFE INC CMN
2026-04-07
Ro Khanna
BUY $1,001 - $15,000 — METLIFE, INC. CMN
2025-10-03
Rohit KhannaD-CA
SELL $1,001 - $15,000 — METLIFE, INC. CMN
2025-10-03
Gilbert CisnerosD-CA
SELL $1,001 - $15,000 — MetLife, Inc. Common Stock
2025-09-12
Rohit KhannaD-CA
SELL $1,001 - $15,000 — METLIFE, INC. CMN
2025-09-09
Ritchie John TorresD-NY
SELL $1,001 - $15,000 — MetLife, Inc. Common Stock (MET)
2025-08-20
Ro Khanna
BUY $1,001 - $15,000 — Metlife Inc
2025-07-10
Rohit KhannaD-CA
BUY $1,001 - $15,000 — METLIFE, INC. CMN
2025-07-09
Rohit KhannaD-CA
BUY $1,001 - $15,000 — METLIFE, INC. CMN
2025-05-12
Sheldon Whitehouse
SELL $1,001 - $15,000 — Metlife Inc
2024-12-05
Rohit KhannaD-CA
BUY $1,001 - $15,000 — METLIFE, INC. CMN
2024-09-06
Rohit KhannaD-CA
SELL $1,001 - $15,000 — METLIFE, INC. CMN
2024-06-05
Thomas R. Carper
SELL $1,001 - $15,000 — Metlife Inc
2024-02-02
Ro Khanna
BUY $1,001 - $15,000 — Metlife Inc
2023-11-08
Sheldon Whitehouse
SELL $1,001 - $15,000 — Metlife Inc
2023-10-17
Ro Khanna
BUY $1,001 - $15,000 — Metlife Inc
BUY $1,001 - $15,000 — Metlife Inc
2023-06-12
Zoe Lofgren
SELL $1,001 - $15,000 — Metlife Inc
2023-06-06
Ro Khanna
SELL $15,001 - $50,000 — Metlife Inc
2023-05-08
Ro Khanna
BUY $15,001 - $50,000 — Metlife Inc
2023-04-07
Rohit KhannaD-CA
SELL $1,001 - $15,000 — METLIFE, INC. CMN
2023-04-07
Ro Khanna
SELL $1,001 - $15,000 — Metlife Inc
2023-01-03
Ro Khanna
BUY $1,001 - $15,000 — Metlife Inc
2022-10-07
Kathy Manning
SELL $1,001 - $15,000 — MetLife, Inc.
2022-09-14
Ro Khanna
BUY $1,001 - $15,000 — Metlife Inc
2022-09-08
Kathy Manning
BUY $1,001 - $15,000 — Metlife Inc
2022-08-10
Ro Khanna
SELL $50,001 - $100,000 — Metlife Inc
2022-08-09
Ro Khanna
SELL $1,001 - $15,000 — Metlife Inc
BUY $1,001 - $15,000 — Metlife Inc
2022-07-07
Ro Khanna
BUY $15,001 - $50,000 — Metlife Inc
BUY $1,001 - $15,000 — Metlife Inc
2022-06-10
John Rutherford
SELL $1,001 - $15,000 — Metlife Inc
2022-04-19
Ro Khanna
BUY $1,001 - $15,000 — Metlife Inc
2022-02-08
Thomas R. Carper
SELL $1,001 - $15,000 — MetLife, Inc. Common Stock
2022-02-03
Ro Khanna
BUY $1,001 - $15,000 — METLIFE INC
SELL $1,001 - $15,000 — METLIFE INC
SELL $1,001 - $15,000 — Metlife Inc.
2021-07-13
Marie Newman
SELL $1,001 - $15,000 — MetLife Inc
BUY $1,001 - $15,000 — MetLife Inc
SELL $1,001 - $15,000 — MetLife Inc
2021-05-09
Ro Khanna
SELL $1,001 - $15,000 — MetLife Inc CMN
2021-04-16
Ro Khanna
BUY $1,001 - $15,000 — Metlife inc CMN (2020 Irrev Trust FBO Grandchildren)
2021-03-12
Joseph D. Morelle
SELL $1,001 - $15,000 — Metlife, Inc.
2020-12-09
Thomas R. Carper
BUY $1,001 - $15,000 — MetLife, Inc.
2020-05-04
Gilbert Cisneros
BUY $1,001 - $15,000 — MetLife, Inc.
2020-04-16
Mikie Sherrill
SELL $1,001 - $15,000 — Metlife, Inc.
2020-04-05
Bill Flores
BUY $15,001 - $50,000 — Metlife, Inc.
2019-08-12
John Hoeven
BUY $50,001 - $100,000 — MetLife, Inc.
2019-04-09
John Hoeven
BUY $50,001 - $100,000 — MetLife, Inc.
2018-06-14
Patty Murray
SELL $1,001 - $15,000 — MetLife, Inc.
2017-06-22
Patty Murray
BUY $1,001 - $15,000 — MetLife, Inc.
2017-03-21
Sheldon Whitehouse
BUY $1,001 - $15,000 — MetLife, Inc.
2016-09-09
Sheldon Whitehouse
BUY $1,001 - $15,000 — MetLife, Inc.
2016-04-04
Susan M. Collins
SELL $1,001 - $15,000 — MetLife, Inc. (NYSE)
2014-12-01
Benjamin Cardin
SELL $1,001 - $15,000 — MetLife, Inc. (NYSE)
2014-11-29

Congressional Legislation Affecting MetLife, Inc. ($MET)

Senator Wyden's PPLI Abuse Act (S.4279) is a single-sponsor bill in early committee stage that would strip tax benefits from PPLI contracts for accredited investors. Near-term market impact is minimal — stocks like MET ($80.35, +13.62% 30-day) and PRU ($97.69, flat 30-day) show no reaction. The bill is a signal of potential broader tax reform in 2027, not a current earnings driver.

→ PPLI contracts would lose all tax deferral and income tax exclusion benefits, making them economically equivalent to taxable investment accounts. Revenue from new PPLI issues would drop to near zero for pass-through contracts; existing contracts would face surrender or restructuring pressure.

S4279

S.4196 is an early-stage bill that would dramatically reduce estate and gift tax exemptions and raise top rates to 45%, but it has no near-term market impact. The bill was introduced on March 25, 2026, read twice, and referred to the Senate Finance Committee with zero subsequent action. No revenue estimates, no hearings, no CBO score, and no companion bill in the House exist. Wealth management firms, high-net-worth estate planning practices, and life insurance companies would be structurally affected only if this bill advanced — which it has not.

S4196

The Living Donor Protection Act of 2025 (S.1552), reported favorably out of committee and on the Senate calendar, prohibits life, disability, and long-term care insurers from discriminating against living organ donors. This removes an underwriting barrier, expands the insured pool, and drives increased transplant volume. Major managed care and insurance stocks have rallied 9-39% in the last 30 days, with this legislation providing a structural tailwind for revenue growth across the sector.

→ Removes a discriminatory underwriting barrier, expanding MetLife's addressable market for group and individual life, disability, and long-term care products by an estimated several thousand potential policyholders annually.

S1552

The Insurance Data Protection Act (HR3437) eliminates direct federal subpoena power over insurers and restricts federal data collection from insurance companies, requiring regulators to obtain data from state authorities first. This is a clear regulatory relief bill for the entire insurance sector. Real market data shows strong 30-day momentum across insurance stocks — MET +13.29%, UNM +10.84%, LNC +6.73%, ALL +4.11%, TRV +4.46% — indicating the market is pricing in sector tailwinds that could accelerate if this bill gains legislative traction.

→ Eliminates the ability of federal regulators to compel insurers to produce internal data without going through state insurance commissioners. This reduces compliance burden, legal exposure from subpoenas, and risk of proprietary underwriting data being shared with federal systemic risk regulators.

HR3437

HR7104 is an early-stage bill that modifies SSDI benefit timing for terminally ill beneficiaries without authorizing new spending. It remains in the House Ways and Means Committee with no hearings or markup scheduled. Market impact is negligible given the bill's procedural status, lack of appropriated funds, and narrow focus on benefit acceleration rather than new program creation.

HR7104

The Insurance Data Protection Act (S1544) eliminates federal subpoena power over insurance companies, reducing compliance costs and protecting proprietary underwriting data. The bill has 11 Republican cosponsors and an identical House companion (HR3437), but remains in early committee stage. Major publicly traded insurers including Allstate, MetLife, Prudential, AIG, and Berkshire Hathaway are direct beneficiaries of reduced regulatory burden and data protection.

→ Removes ability of OFR to subpoena insurance company data for systemic risk monitoring; shifts burden to state insurance regulators. MetLife, as a globally systemically important insurer (G-SII) historically under FSOC scrutiny, directly benefits from elimination of federal data collection pathway.

S1544

The Secure Family Futures Act (HR2547) is an early-stage bill proposing tax relief for insurance companies via debt reclassification and extended loss carryforwards. No near-term market impact: the bill lacks funding measures, has no scheduled markup, and faces a long legislative path. Recent sector stock moves (MetLife +15.6%, Lincoln +9.4%, AIG +1.7% over 30 days) are not attributable to this bill.

→ Debt instrument gains/losses shift from capital gains treatment (lower rate, limited loss offset) to ordinary income treatment (full rate, broader offset); capital losses can be used over 10 years instead of 5, reducing net tax liability on investment losses.

HR2547

Understanding These Signals

Get Full Access to MetLife, Inc. ($MET) Signals

Daily AI-analyzed alerts for Congressional activity affecting your portfolio.

Get Started →